Close menu




October 11th, 2023 | 08:10 CEST

Attention Price Jump! Tui, Plug Power and Defence Therapeutics with News

  • Biotechnology
  • Innovations
  • Technology
  • Travel
Photo credits: pixabay.com

Alarm at Tui and Deutsche Lufthansa. Both stocks are influenced by the terrorist attack in Israel this week. While the oil price is surging, aviation and tourism stocks are declining. The Tui share had already been trending weakly before. Even the leap into the profit zone could not change this. And what do analysts say? Meanwhile, Defence Therapeutics shone with positive news on a cancer therapy. As a result, the biotech share gained yesterday, offering further potential for price increases. Plug Power's share price rose by a good 7% yesterday. What is behind this?

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: TUI AG NA O.N. | DE000TUAG505 , PLUG POWER INC. DL-_01 | US72919P2020 , DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Defence Therapeutics Now Combating Pancreatic Cancer

    The reason for yesterday's share price jump: The unconjugated Accum™ molecule developed by Defence Therapeutics helps fight cancer in two ways, according to a peer-reviewed study. It was published under the title "Intratumoral administration of unconjugated Accum impairs the growth of pre-established solid lymphoma tumors" in the renowned scientific journal (Cancer Science). From Defence Therapeutics' point of view, the effects of Accum™ are highly interesting and unexpected, as the induction of immunogenic cell death introduces an additional immune component that could turn a "cold" tumor into a "hot" one with increased infiltration of immune cells.

    According to the study, Accum™ has many advantages over molecules detected by high-throughput screening. Thus, cancer cells are targeted in two ways at once. First, by directly triggering cell death of various cancer cell lines (T-cell lymphoma, colorectal cancer, melanoma and breast cancer). Secondly, it also acts indirectly by "alerting" the immune system of the affected individual to fight the cancer cells. From Defence Therapeutics' perspective, the study also provides new avenues of research in which more potent Accum™ variants could be tested as an injectable anti-cancer drug.

    The announcement shows that Defence Therapeutics has a highly exciting pipeline. If the positive share price reaction continues in the coming days, the downward trend that has persisted since January could be broken, and an exciting entry opportunity could present itself to investors. From the current price level of EUR 1.75 to the January high, there is a price opportunity of almost 100%.

    Tui: Rebound after all-time low?

    Analysts currently see few price opportunities for the Tui share. Following the quarterly figures, UBS, Bernstein and Jefferies, among others, advise holding the shares of the tourism group. Barclays has at least raised the price target from GBP 4.7 to GBP 6.9. This was also due to a consumer survey with positive results, indicating that foreign trips are still planned for the next twelve months. Nevertheless, the analysts maintain their "Underweight" rating. Only Deutsche Bank currently recommends buying into the tourism group. After a surprisingly strong third quarter, the outlook for the final quarter is also positive. Therefore, their price target is EUR 9.80.

    Tui reported a return to profit for the third quarter. 5.5 million guests traveled with Tui in Q3 2023, representing a year-on-year increase of 9%. The tourism group generated around EUR 5.3 billion in revenue with them, 19% more than in the prior year. Adjusted EBIT improved significantly in Q3 2023 by EUR 196.5 million to EUR 169.4 million (Q3 2022: EUR -27.0 million loss). Due to the good booking situation for Q4, the forecast for the full year was also confirmed. Tui expects a significant increase in adjusted EBIT. Nevertheless, the share is at an all-time low of around EUR 5.

    Plug Power: Bottom reached?

    The Plug Power share sent out a sign of life yesterday. After reaching a multi-year low the previous day, it gained more than 7% yesterday and almost reached USD 7. To put this in perspective, the high for the year is USD 17.38. There was no corporate news responsible for the price jump.

    Things will get interesting for Plug Power shareholders at the latest on November 9. That is when the Company will report on its third-quarter developments. Hopefully, there will also be concrete information about financing until reaching the break-even point. In recent months, there has been repeated speculation about a capital increase.

    The latest news came from a supplier of Plug Power. Cell Impact reported receiving an order from Plug Power with a volume of SEK 22 million. Thus, Cell Impact will manufacture bipolar plates and related products and deliver them to the US company in the first half of 2024. A bipolar plate consists of two poles of a single fuel cell: the hydrogen-carrying anode plate (the negative (-) pole) and the cathode plate (the positive (+) pole) for feeding the reaction air.


    Yesterday's announcement should provide new momentum for Defence Therapeutics' stock. It demonstrates that the Company is building an attractive pipeline. This not only makes the stock interesting for shareholders but may also position the Company as a takeover candidate. At Tui, the operational development seems positive, but the unsuccessful capital increase from the spring still appears to weigh on the stock. The share price speaks a clear language, and analysts are also cautious. Caution also seems warranted for Plug Power. The Group must finally communicate whether a capital increase is coming or how else financing can be secured until reaching the break-even point.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Juliane Zielonka on April 11th, 2024 | 07:45 CEST

    Innovation made in Europe: Singulus Technologies, Siemens Energy, BASF - which share offers the greatest potential?

    • renewableenergies
    • chemicals
    • Technology

    Companies in Europe, like Singulus Technologies, are leaders in the production of surface materials in future-oriented sectors such as photovoltaics, semiconductors, medical technology and cosmetics. This is reason enough to take a closer look at Europe as a location. The European Commission is determined to push ahead with CO₂ reduction with all its might and subsidize future energies. They would prefer to lock out Chinese companies that produce solar and wind turbines more cost-effectively than Siemens Energy. However, China is also an excellent place to do business. Chemical giant BASF strategically adheres to long-term contracts, in line with the Chinese strategist Sun Tzu. Which share offers the greatest potential for investors?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read